ACORN CAPITAL ADVISORS, LLC
An institutional investment manager in NEW YORK, NY. Its Form 13F for the quarter ended Jun 30, 2026, filed Aug 14, 2026. SEC CIK 2054410.
- Reported value$366.5m
- Positions20
Holdings: 20 positions
The filing on sec.govAs filed, largest first. Reported value is what the manager stated for each position at the quarter end, in US dollars; it is filing data, not a price. Weight is the position's share of the total reported value. Changes compare with the 13F for the quarter ended 2026-03-31.
| Issuer | Class | CUSIP | Reported value$m | Weight | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|---|---|
| CG Oncology IncCGON | COM | 156944100 | 80.4 | 21.9% | 1,131,500 | Added+999 | |
| Urogen Pharma Ltd | COM | M96088105 | 61.6 | 16.8% | 1,673,420 | Unchanged | |
| Trevi Therapeutics IncTRVI | COM | 89532M101 | 40.0 | 10.9% | 2,144,844 | Unchanged | |
| Candel Therapeutics IncCADL | COM | 137404109 | 36.0 | 9.8% | 3,497,948 | Unchanged | |
| Puma Biotechnology IncPBYI | COM | 74587V107 | 33.5 | 9.1% | 4,131,299 | Unchanged | |
| Jade Biosceinces IncJBIO | COM NEW | 008064206 | 21.9 | 6.0% | 986,760 | Added+200,000 | |
| Bicara TherapeuticsBCAX | COM | 055477103 | 19.1 | 5.2% | 643,381 | Reduced−1 | |
| Karyopharm Therapeutics IncKPTI | COMMON STOCK | 48576U205 | 14.8 | 4.0% | 1,518,113 | Added+1,230,287 | |
| Onkure Therapeutics IncOKUR | CLASS A COM | 68277Q105 | 12.9 | 3.5% | 2,839,674 | Unchanged | |
| Helus Pharma Inc. | COM STK | 23256X407 | 10.2 | 2.8% | 1,540,266 | Unchanged | |
| Protara Therapeutics IncTARA | COM STK | 74365U107 | 6.7 | 1.8% | 1,752,115 | Unchanged | |
| Aura Biosciences IncAURA | COM | 05153U107 | 6.6 | 1.8% | 929,077 | Added+333,333 | |
| Leonabio, Inc.LONA | COMMON STOCK | 04746L203 | 5.8 | 1.6% | 634,539 | Unchanged | |
| Verastem IncVSTM | COM | 92337C203 | 5.6 | 1.5% | 1,469,153 | Unchanged | |
| Whitehawk Therapeutics IncWHWK | COM | 00032Q104 | 5.2 | 1.4% | 1,139,363 | Unchanged | |
| Q32 Bio Inc.QTTB | COM | 746964105 | 2.8 | 0.8% | 216,171 | Reduced−98,881 | |
| Eugene TherapeuticsENGN | COM | 29286X101 | 2.2 | 0.6% | 1,271,257 | New+1,271,257 | |
| Jasper TherapeuticsJSPR | COM | 471871202 | 0.6 | 0.2% | 1,438,159 | Added+26,667 | |
| Bioatla Inc | COM | 09077B104 | 0.4 | 0.1% | 108,126 | Reduced−5,298,219 | |
| Vyne Therapeutics Inc | COM | 92941V308 | 0.0 | <0.1% | 1,425 | Unchanged |
Sold out: 3 positions
Held at the end of the quarter before and not reported this quarter.
| Issuer | Class | CUSIP | Reported value$ | Weight | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|---|---|
| Cardif Oncology IncCRDF | COM | 14147L108 | 0.0 | 0.0% | 0 | Sold out−1,762,084 | |
| Terns Pharmaceuticals Inc | COM | 880881107 | 0.0 | 0.0% | 0 | Sold out−1,746,264 | |
| X4 Pharmaceuticals Inc | COM | 98420X103 | 0.0 | 0.0% | 0 | Sold out−234,039 |
Source: SEC EDGAR, Form 13F-HR, accession 0001636587-26-000067 (on sec.gov). Last ingested by Listed: Oct 22, 2026, 05:26 ET. Listed shows no prices and gives no investment advice.